Tesaro Inc. is moving forward with ambitions to expand the poly ADP-ribose polymerase (PARP) inhibitor Zejula (niraparib) to more indications beyond recurrent ovarian cancer, including as a front-line treatment for ovarian cancer, in combination with the immunotherapy Keytruda (pembrolizumab), in triple-negative breast cancer and lung cancer.
Management outlined the expansion strategy and some encouraging early data during an investor briefing at the American Society of Clinical...